Background: This study sought to evaluate the effect of basic fibroblast growth factor eye drops and cysteine oral supplements on corneal healing in patients treated with photorefractive keratectomy (PRK). Materials and Methods: One hundred and twenty patients treated bilaterally with PRK for myopia were enrolled at one of two eye centers
The surgical treatment of myopia has achieved significant progress over the last 20 years with the introduction of photorefractive keratectomy (PRK). Improvements in laser technology have improved the safety and refractive stability of PRK, allowing the surgeon to leave a smoother stromal bed and provide a reduced incidence of haze after the surgical procedure. [1] [2] [3] Corneal epithelial cell removal is generally performed using an alcohol-assisted procedure that does not result in keratocyte apoptosis. [4, 5] Because keratocyte apoptosis represents the initial step of subepithelial fibrosis, the use of alcohol to remove the epithelium enables more rapid visual and refractive recovery with less corneal haze. [3] To the best of our knowledge, several reports have compared the visual and refractive outcomes of different corneal epithelium removal techniques. [6] Ultraviolet radiation at a wavelength of 193 nm is then used to perform laser photoablation of Bowman's layer and the anterior corneal stroma. Surface ablation directly exposes the anterior stromal keratocytes to the effects of cytokines, growth factors and enzymes, such as matrix metalloproteinases (MMP), which are released by the injured ocular surface. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The keratocyte is the most abundant cell type within the corneal stroma; these cells are mesenchymal in origin and lie between the collagen lamellae of the corneal stroma. The cells are also responsible for synthesizing the stromal extracellular matrix (ECM) and, in certain situations, regeneration may occur without scarring as a result of keratocyte proliferation and migration to replace lost cells. In addition, the process of keratocyte renewal may depend on a subpopulation of progenitor or stem cells; indeed, several studies have demonstrated the existence of corneal stromal stem cells and have shown that keratocytes are capable of movement within the corneal stroma. [24, 25] Furthermore, several components of the tear film, such as inflammatory cells, molecules from the extracellular matrix, corneal epithelial cells and corneal stromal fibroblasts, are able to modify the complex biological process of corneal wound healing, and previous studies have demonstrated how growth factors affect corneal wound healing after PRK. [8] [9] [10] [11] [12] [13] [14] [15] [16] Visual rehabilitation after PRK depends on epithelial repopulation and stromal healing without fibrosis, and it was recently reported that the topical application of neurotrophic substances, such as growth factors, can promote corneal wound healing (references). We recently demonstrated that the topical application of basic fibroblast growth factor (b-FGF) is safe and effective in promoting epithelial and stromal healing after PRK; specifically, b-FGF promotes the proliferation of epithelial and stromal cells and affects the remodeling of the ECM. [17, 18] This growth factor has also been shown to be expressed in almost all tissues of mesodermal and neuroectodermal origin. Furthermore, the levels of endogenous b-FGF have been shown to increase at sites of injury, suggesting that its release and activation from intracellular and extracellular sources may be an integral part of the wound healing process. [26] [27] [28] [29] [30] Initially, the effect of b-FGF on corneal wound healing was investigated both in rabbits and in transgenic mice, and these studies reported significant improvement in epithelial healing after PRK. [31] [32] [33] [34] [35] In the present study, we investigated the efficacy of b-FGF eye drops combined with L-cysteine oral supplementation for the treatment of corneal epithelial healing after PRK in myopic patients. As 1 week may be required to recover an intact epithelium and several weeks before best-corrected visual acuity (BCVA) is achieved, we tested whether this pharmacological combination could expedite epithelial healing and improve pain after PRK.
Materials and Methods
One hundred and twenty patients (240 eyes), who were between the ages of 30 and 45 years (mean age = 37.3 ± SD 2.3 years) and were treated bilaterally with PRK for myopia (mean = −4.5 ± SD 1.5 D) were enrolled in this prospective randomized study.
This study was conducted according to the procedures of the Declaration of Helsinki. All subjects provided written informed consent after the nature of the procedures had been explained in detail. We enrolled patients using the following inclusion criteria: Mean spherical equivalent (SE) within the range − 3 and − 6 D, BCVA equal to or greater than 20/25 and corneal central thickness (CCT) within the range of 540 microns and 550 microns. All subjects with ocular disease (which could cause a deficit in visual functionality), diabetic retinopathy, glaucoma, diseases affecting the anterior segment, macular degeneration, either vitreous or retinal disorders, retinal vasculopathies, anterior and/or posterior uveitis and systemic disorders (which could affect the ocular system and modify the corneal healing process) were excluded from this study. [16, 17] We also excluded patients with any evidence of lid disease, progressive or unstable myopia and keratoconus, a history of herpetic keratitis and previous intraocular and/or corneal surgery. All subjects included in the study were randomized into two treatment groups (Group 1 and Group 2). Sixty patients were included in the study group (Group 1) and were treated postoperatively with standard topical antibiotics, corticosteroids, artificial tear therapy and topical b-FGF eye drops plus oral L-cysteine supplements. In addition, 60 subjects were included in the control group (Group 2) and received standard topical antibiotics, corticosteroids and artificial tears as postoperative therapy plus b-FGF eye drops only. All patients enrolled were evaluated the day prior to surgery (visit 0) and received a complete ophthalmological examination, including BCVA, biomicroscopy, tonometry (Altair ultrasonic pachymeter; Optikon 2000, Rome, Italy), corneal endothelial cell count (Cellcheck XL; Konan Medical Inc, Irvine, CA USA), topography (CSO CM02/CM-P02, CSO, Florence, Italy) and funduscopy evaluation. All patients received corneal pachymetry to measure the central corneal thickness and corneal topography to map the curvature of the corneal surface. Tear function was assessed using Shirmer's test without corneal anesthesia, and we also determined the tear film breakup time (BUT). Soft contact lens wearers were invited to discontinue use for a minimum of 3 days prior to surgery, while rigid gas-permeable contact lens wearers were required to suspend use for a minimum of 3 weeks prior to the ophthalmological examination performed the day before surgery. A single operator carried out the refractive procedure. PRK was performed using a Schwind Esiris excimer laser (Schwind GmbH, Germany) with an emission wavelength of 193 nm. This excimer laser uses a 0.8 mm flying spot, a Gaussian bean with a repetition rate of 250 Hz and a 250 Hz infrared eye tracker, which monitors the pupil margin and centers the ablation on the entrance pupil center. All surgical procedures took place between 9 am and 1 pm Preoperatively, patients were treated with oxibuprocaina hydrochloride 0.4% (Novesina 0.6 mL 0.4%, Novartis Farma Spa, Italy) and the eye lashes and lids were treated with a povidone-iodine swab. The surgeon marked a 9.0-mm zone with an approved dye, centering it over the image of the pupil. Ethyl alcohol (90%) diluted in physiological saline solution (20%) was used to remove the central 9 mm of the corneal epithelium. This was followed by laser photoablation of both the Bowman's layer and the anterior corneal stroma. After PRK, a contact lens was applied and all patients received the standard topical medication recommended by the current guidelines, consisting of topical tobramycin (Tobral 0.3%; Alcon, TX, USA) and diclofenac eye drops (Voltaren-ofta 0.1%; Novartis, Italy) every 6 h for the first week, followed by twice a day for 1 month. Artificial tears were applied every hour until corneal epithelial healing was completed (Hyaluronate 0.2%; Hyalistil, Sifi, Italy). Subjects included in Group 1 also received topical medication with b-FGF at dose of 10 μg per 10 μL (recombinant b-FGF, Prodotti Gianni, Italy) four times a day (every 6 h) for 7 days beginning on the day of surgery. These patients were also treated with oral L-cysteine supplements (L-Cysteine; Natural Point S.r.l., Italy) at dose of 500 mg once a day for a period of 15 days beginning 7 days prior to PRK. Patients in Group 2 were treated with b-FGF eye drops only. Beginning on the day after surgery, all subjects were evaluated daily until corneal healing appeared complete by biomicroscopy and corneal central thickness was increased according to pachimetry. We also recorded the rate of corneal re-epithelialization using daily slit-lamp evaluation.
The follow-up period lasted 6 months, during which time all patients underwent complete ophthalmological examinations every 30 days, including BCVA, slit-lamp biomicroscopic observation, applanation tonometry, pachimetry and retina examination. During the follow-up visits, the physician also observed the haze levels.
All data were subjected to statistical analysis. We performed the Student's t test for unpaired samples to evaluate differences in means between the two treatment groups. We also calculated the P value to define the statistical significance of the results, with P ≤ 0.05 considered statistically significant. All statistical calculations were performed using the MedCalc 11.4.1.0 software.
Results
There were no significant differences in preoperative variables between the two groups and the variables followed a Gaussian distribution. However, the re-epithelialization rates differed between Group 1 and Group 2.
Complete corneal epithelial resurfacing was achieved starting at Day 3 after PRK in 57% of the eyes included in the study group (Group 1) and in 44% of the eyes in the control group (Group 2). At Day four, 99% of the eyes included in Group 1 showed complete healing, while just 89% of the eyes in Group 2 achieved the same result. Furthermore, we observed complete re-epithelialization in all patients treated with topical b-FGF eye drops plus oral L-cysteine supplementation at Day 5, while the patients in Group 2, who were treated with topical b-FGF only, did not achieve complete resurfacing until Day 6 or Day 7 after the surgical procedure. Moreover, subjects treated with b-FGF plus L-cysteine demonstrated a re-epithelialization time of 3.3 days ± SD 0.3, whereas patients treated with b-FGF only required a longer time to achieve a complete re-epithelialization (4.8 days ± SD 0.5). The Kaplan-Meier curves also demonstrated a statistically significant difference between the two groups (P < 0.0001) from Day 3 to Day 5 postsurgery [ Fig. 1] . No statistically significant differences were observed regarding haze prevalence or BCVA after PRK between Group 1 and Group 2.
All subjects treated in both groups showed a BCVA that ranged from 20/25 to 20/20, and no loss of lines of the BCVA was detected in either group.
No side-effects related to the treatments were reported during the study and none of the subjects were lost to follow-up during the 6-month follow-up period. Trace to mild corneal haze was observed in both groups, including in four eyes of the study group and six eyes of the control group, and statistical analysis did not show any significant differences between the two groups.
Discussion
Prompt corneal restoration after injury, both surgical and accidental, is required to maintain the optical properties of the eye. Furthermore, proper restoration of the epithelial layer is necessary for stromal recovery and to promote the stromal phase of wound healing. Altered epithelial repair induces excessive and disorganized stromal healing, with alterations to the corneal transparency and impairments in visual function. The degree and extent of keratocyte apoptosis also varies with the type of overlying epithelial injury, and can be influenced by the surgical technique and drugs. Therefore, rapid re-epithelialization of the cornea would likely promote wound healing of the underlying stroma with minimal cell apoptosis. [38] Furthermore, the identification of factors that aid re-epithelialization after corneal epithelial injury and prevent complications related to delayed cicatrization, such as scar or haze formation, would optimize surgical outcomes. [39, 40] Additionally, more rapid epithelial healing has been shown to limit postoperative problems such as haze formation. [38] [39] [40] Several growth factors, vitamins and amino acids have also been shown to have a primary and active role in corneal re-epithelialization after corneal injury. [41] [42] [43] [44] [45] [46] These substances improve corneal haze and speed the complex process of corneal epithelial healing. [47] Growth factors are also known to play a primary role both in corneal wound healing and in remodeling of the ECM.
The production of growth factors by corneal cells and their presence in tears is essential for the maintenance and renewal of normal tissue and the prevention of undesirable immune or angiogenic reactions. The wound healing response following excimer laser corneal photoablation has been extensively studied at the clinical, microscopic, ultrastructural and immunohistochemical levels, [8] and these findings have provided considerable evidence supporting the close relationship between the structural and the biological wound healing responses of the cornea and the resulting optical clarity and stability of the intended refractive change. In addition, the efficacy of recombinant human b-FGF on epithelial healing has been demonstrated in rabbits after mechanical anterior keratectomy. [31] [32] [33] [34] [35] 44, 45] In this study, we found that patients treated with both b-FGF eye drops and L-cysteine oral supplements benefited from more rapid corneal re-epithelialization, which indicates that these two compounds, which act at different subcellular sites, may deliver synergistic effects when used in combination. [48] Moreover, this combination appeared to be safe on human eyes and more effective than topical b-FGF treatment alone. However, no significant differences in corneal haze formation or BCVA were noted between the two groups. Further studies are needed to test this innovative treatment in patients with an expected delay in corneal epithelium healing and to expand the treatment's potential application to other corneal pathological diseases. 
